Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficiency of autologous CD19/CD22 CAR-T lymphocytes in a cohort of pediatric and young adult patients with relapsed /refractory B-lineage acute lymphoblastic leukemia


Clinical Trial Description

The main objectives of the study are: - To investigate the incidence of adverse events of grade 3-5 within after CD19/CD22 CAR lymphocyte infusion by day 28, - To evaluate the incidence of complete remission and MRD-negative CR by day 28 - To evaluate the long-term effectiveness of CD19/CD22 CAR-T therapy (cumulative incidence of relapse, event-free survival, overall survival) at 1, 2, and 5 years after infusion. - To evaluate the persistence of CD19/CD22 CAR-T cells and duration of B-cell aplasia (<1% B-cells in the blood) and hypogammaglobulinemia In order to prevent the development of CRS, all patients will receive an infusion of tocilizumab at 8 mg/kg body weight on day 0 before CAR-T cells infusion. Step-down and step-up dosing will be used to adapt the trial to the scenario of excess toxicity and/or suboptimal effect. Reevaluation of dosing will be done for each cohort separately after the enrollment 5th study subject reaches day 28 or earlier if the threshold for excess toxicity or suboptimal effect is achieved. Based on interim analysis in March 2021 after the enrollment 5th study subject reaches day 28 study population will be divided into three cohorts: 1. CD19-positive (both CD19 and CD22 expressed on over 50% of leukemia cells), low and high disease burden. 2. CD19-negative (CD22 expressed on over 50% of leukemia cells) low and high disease burden; 3. Allogeneic HSCT+ allogeneic CAR-T cohort ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04499573
Study type Interventional
Source Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date July 27, 2020
Completion date March 13, 2027

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04088890 - Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies Phase 1
Recruiting NCT04546906 - Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia N/A
Recruiting NCT04546893 - Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia N/A
Active, not recruiting NCT01209286 - Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) Phase 2
Withdrawn NCT05571540 - Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL Phase 1/Phase 2
Completed NCT01290120 - Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma Phase 2
Recruiting NCT04781634 - a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL Phase 1/Phase 2
Recruiting NCT03448393 - CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies Phase 1
Recruiting NCT05350852 - Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL Phase 1
Recruiting NCT05350787 - Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL Phase 1
Recruiting NCT05621291 - A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu... N/A
Active, not recruiting NCT04318678 - CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) Phase 1
Recruiting NCT04512716 - Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma Early Phase 1
Active, not recruiting NCT03751709 - Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL Phase 1
Recruiting NCT05639179 - Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL Phase 1/Phase 2
Recruiting NCT04792593 - Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia N/A
Recruiting NCT05442515 - CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies Phase 1/Phase 2
Active, not recruiting NCT02328014 - Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies Phase 1/Phase 2
Active, not recruiting NCT02315612 - Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies Phase 1